In Committee
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Sponsor
Rep. Harshbarger, Diana [R-TN-1]Republican · TennesseeCommittee
Energy and Commerce CommitteeLast action
Referred to the House Committee on Energy and Commerce.
Jan 22, 2025
Referred to the House Committee on Energy and Commerce. · Jan 22, 2025
Introduced Jan 22, 2025
Members signed on after the sponsor
Offered against this measure
No roll calls stored
3 organizations reported lobbying on this bill.
From Lobbying Disclosure Act reports that name this bill. Reports do not say how much of a quarter's spending went to any one bill, so none is attributed here.